PRESS RELEASES

PRESS RELEASES

July 20, 2016
Second Quarter 2016 Revenue in the range of $21.45 million to $21.65 million Core recurring revenue to increase 5.6% to 6.6% over the same period last year EBITDA projected to be $300,000-$400,000 for Second Quarter 2016 BELGRADE, Mont. , July 20, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings,
May 17, 2016
BELGRADE, Mont. , May 17, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), formerly Bacterin International Holdings, Inc. , a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today announced that its Chief
May 13, 2016
BELGRADE, Mont. , May 13, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, has established a record date for its 2016 annual meeting of stockholders.
May 4, 2016
See footnote about the use of pro forma financial information First Quarter 2016 Highlights: Core recurring revenue (excluding OEM and other revenue) increased 6.8% to $20.5 million compared to core pro forma recurring revenue of $19.2 million in first quarter 2015 Gross profit increased slightly